Loading...
XNYSHAE
Market cap3.92bUSD
Jan 08, Last price  
78.10USD
1D
0.49%
1Q
4.90%
Jan 2017
94.28%
Name

Haemonetics Corp

Chart & Performance

D1W1MN
XNYS:HAE chart
P/E
33.37
P/S
3.00
EPS
2.34
Div Yield, %
0.00%
Shrs. gr., 5y
-0.59%
Rev. gr., 5y
6.23%
Revenues
1.31b
+12.01%
383,598,000419,733,000449,607,000516,440,000597,879,000645,430,000676,694,000727,844,000891,990,000938,509,000910,373,000909,675,000886,116,000903,923,000967,579,000988,479,000870,463,000993,196,0001,168,660,0001,309,055,000
Net income
118m
+1.87%
39,639,00069,076,00049,109,00051,980,00059,304,00058,375,00079,980,00066,886,00038,800,00035,148,00016,897,000-55,620,000-26,268,00045,572,00055,019,00076,526,00079,469,00043,375,000115,401,000117,558,000
CFO
182m
-33.44%
71,207,00085,616,00083,563,00077,669,000116,364,000130,668,000123,455,000115,318,00085,074,000139,524,000127,178,000121,865,000159,738,000220,350,000159,281,000158,217,000108,805,000172,263,000273,058,000181,751,000
Earnings
Feb 06, 2025

Profile

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
IPO date
Oct 17, 1979
Employees
3,034
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
1,309,055
12.01%
1,168,660
17.67%
993,196
14.10%
Cost of revenue
1,103,722
980,369
874,058
Unusual Expense (Income)
NOPBT
205,333
188,291
119,138
NOPBT Margin
15.69%
16.11%
12.00%
Operating Taxes
34,307
26,002
20,254
Tax Rate
16.71%
13.81%
17.00%
NOPAT
171,026
162,289
98,884
Net income
117,558
1.87%
115,401
166.05%
43,375
-45.42%
Dividends
Dividend yield
Proceeds from repurchase of equity
(75,000)
6,547
BB yield
1.76%
-0.20%
Debt
Debt current
10,229
11,784
214,148
Long-term debt
855,522
817,167
566,637
Deferred revenue
Other long-term liabilities
75,041
74,715
79,876
Net debt
686,951
544,485
521,289
Cash flow
Cash from operating activities
181,751
273,058
172,263
CAPEX
(66,296)
(110,191)
(96,509)
Cash from investing activities
(322,389)
(143,788)
(86,345)
Cash from financing activities
38,157
(100,364)
(15,749)
FCF
60,556
133,079
54,306
Balance
Cash
178,800
284,466
259,496
Long term investments
Excess cash
113,347
226,033
209,836
Stockholders' equity
325,332
223,291
176,948
Invested Capital
1,729,446
1,435,307
1,412,033
ROIC
10.81%
11.40%
7.07%
ROCE
10.78%
11.11%
7.36%
EV
Common stock shares outstanding
51,397
51,420
51,353
Price
85.35
3.14%
82.75
29.60%
63.85
-43.01%
Market cap
4,386,734
3.10%
4,255,005
29.77%
3,278,889
-42.94%
EV
5,073,685
4,799,490
3,800,178
EBITDA
302,548
281,598
216,885
EV/EBITDA
16.77
17.04
17.52
Interest
13,018
14,630
17,121
Interest/NOPBT
6.34%
7.77%
14.37%